Disease · EFO_0006835
pyoderma gangrenosum
6 sourcesdiseases-2026-09-18-0.1.0
Cite this record
ConductScience Library. pyoderma gangrenosum. Diseases, record EFO_0006835. Release diseases-2026-09-18-0.1.0, 18 Sept 2026. https://conductscience.org/library/diseases/EFO_0006835
On this page
Disease
Names and IDs as Open Targets gives them. Its IDs in MeSH, Orphanet, the Disease Ontology and the NCI Thesaurus are those Open Targets states for it.
- Highest stage of its drugs
- Phase 3, for 4 of its 11 drugs, from ClinicalTrials.gov and TTD
- Open Targets
Drugs11
The drugs Open Targets' clinical reports study for the disease, the highest stage first, then the most trial reports. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.
| Drug | ChEMBL ID | Type | Open Targets' stage | Stage reported by | Reports | Of them trials | Trials shown here | Source |
|---|---|---|---|---|---|---|---|---|
| PREDNISOLONE | CHEMBL131 | Small molecule | Phase 3 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
| PREDNISONE | CHEMBL635 | Small molecule | Phase 3 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
| SPESOLIMAB | CHEMBL4297911 | Antibody | Phase 3 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
| SIVELESTAT | CHEMBL76688 | Small molecule | Phase 3 | TTD | 1 | 0 | 0 | Drugs and targets |
| BARICITINIB | CHEMBL2105759 | Small molecule | Phase 2 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
| GUSELKUMAB | CHEMBL2364648 | Antibody | Phase 2 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
| BERMEKIMAB | CHEMBL2109653 | Antibody | Phase 2 | TTD | 1 | 0 | 0 | Drugs and targets |
| ETRASIMOD | CHEMBL3358920 | Small molecule | Phase 2 | TTD | 1 | 0 | 0 | Drugs and targets |
| INFLIXIMAB | CHEMBL1201581 | Antibody | Unknown | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
| TOMINERSEN | CHEMBL4297581 | Oligonucleotide | Unknown | USAN | 1 | 0 | 0 | Drugs and targets |
1 to 10 of 11
See all 11 drugsTargets15
The targets ChEMBL's mechanism records give for the disease's drugs, through Open Targets, the most drugs first. A mechanism record says what a drug acts on, not that the target causes the disease.
| Target | Protein | Its drugs that act on it | Mechanisms | Highest stage of those drugs | Gene in Genes | Source |
|---|---|---|---|---|---|---|
| NR3C1 | Glucocorticoid receptor | 2 | Glucocorticoid receptor agonist | Phase 3 | https://conductscience.org/library/genes/2908 | Drugs and targets |
| C5 | Complement C5 | 1 | Complement C5 inhibitor | Unknown | https://conductscience.org/library/genes/727 | Drugs and targets |
| ELANE | Neutrophil elastase | 1 | Leukocyte elastase inhibitor | Phase 3 | https://conductscience.org/library/genes/1991 | Drugs and targets |
| HTT | Huntingtin mRNA | 1 | Huntingtin mRNA antisense inhibitor | Unknown | https://conductscience.org/library/genes/3064 | Drugs and targets |
| IL12B | Interleukin-23 | 1 | Interleukin-23 inhibitor | Phase 2 | https://conductscience.org/library/genes/3593 | Drugs and targets |
| IL1A | Interleukin-1 alpha | 1 | Interleukin-1 alpha inhibitor | Phase 2 | https://conductscience.org/library/genes/3552 | Drugs and targets |
| IL1RAP | IL36 receptor | 1 | IL36 receptor antagonist | Phase 3 | https://conductscience.org/library/genes/3556 | Drugs and targets |
| IL23A | Interleukin-23 | 1 | Interleukin-23 inhibitor | Phase 2 | https://conductscience.org/library/genes/51561 | Drugs and targets |
| IL36R | IL36 receptor | 1 | IL36 receptor antagonist | Phase 3 | https://conductscience.org/library/genes/8808 | Drugs and targets |
| JAK1 | Tyrosine-protein kinase JAK1 | 1 | Tyrosine-protein kinase JAK1 inhibitor | Phase 2 | https://conductscience.org/library/genes/3716 | Drugs and targets |
1 to 10 of 15
See all 15 targetsTrials4
Trials an Open Targets clinical report links to the disease, posted results first, then the largest. A trial is shown when the release's checks confirm its link to the disease and Drugs and targets shows its link to one of the disease's drugs.
| Trial | Title | Phase | Participants | Results first posted | Conditions | Drugs | Linked by | Source |
|---|---|---|---|---|---|---|---|---|
| NCT00791557 | Open Label Study for Adults With Pyoderma Gangrenosum and Inflammatory Bowel Disease | Not applicable | 2 | 2013-11-15 | Pyoderma Gangrenosum, Crohn's Disease, Ulcerative Colitis, Inflammatory Bowel Disease | INFLIXIMAB | Its record names the disease | ClinicalTrials.gov |
| NCT06624670 | A Study to Test Whether Spesolimab Helps People With a Skin Condition Called Pyoderma Gangrenosum | Phase 3 | 90 | Pyoderma Gangrenosum | PREDNISOLONE, PREDNISONE, SPESOLIMAB | Its record names the disease | ClinicalTrials.gov | |
| NCT06563323 | Guselkumab in the Treatment of Adults With Pyoderma Gangrenosum (PG) | Phase 2 | 17 | Pyoderma Gangrenosum, Skin Diseases, Wound Heal, Pyoderma, Skin Ulcer | GUSELKUMAB | Its record names the disease | ClinicalTrials.gov | |
| NCT04901325 | Baricitinib in the Treatment of Adults With Pyoderma Gangrenosum (PG) | Phase 2 | 5 | Pyoderma Gangrenosum, Skin Diseases, Wound Heal, Pyoderma, Skin Ulcer | BARICITINIB | Its record names the disease | ClinicalTrials.gov |
Comparisons in its trials0
Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.
None in this release.
Papers from its trials0
The papers the trials shown here list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.
None in this release.
Data dates
The date of each source this release read.
Sources 6
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- NLM's MeSHNLM's terms
- Open TargetsCC0 1.0
- PubMedNLM's terms
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- NLM's MeSHNLM's
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this disease from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/diseases/v1/EFO_0006835
GET https://conductscience.org/api/diseases/v1/EFO_0006835/drugs